Project subject to legal proceedings with date set before High Court of Greenland Special Report: Energy Transition Minerals has appointed US-based advisers as it looks to list on the Nasdaq stock ...

ETM asks Greenland High Court to remove Denmark from case after recent legal wins Move clears path for substantive hearing on Kvanefjeld licence claim Company remains open to finding common ground ...

Make sure not to miss this valuable item your first time around. When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Add us as a preferred source on ...

Qualys, Inc. (QLYS) recently reported its Q3 financial results, beating both revenue and earnings estimates. I previously analyzed QLYS in April, upgrading it with a Hold outlook due to improved ...

Energy Transition Minerals forms Advisory Board and adds two appointments The board will support the company’s engagement with Greenlandic and Danish stakeholders Further appointments to the board are ...

Qualys has strengthened its Enterprise TruRisk Management (ETM) platform by integrating an agentic AI fabric, expanding support for managing both human and non-human identities, delivering ...

In many a school auditorium, a theater kid could be spotted sitting cross-legged with a peanut butter and jelly sandwich, surrounded by peers who had just belted their way through the entire Hamilton ...

Camcevi ETM contains 21mg of leuprolide and is administered every 3 months. The Food and Drug Administration (FDA) has approved Camcevi ETM ®, a long-acting formulation of leuprolide mesylate, for the ...

Camcevi ETM, a long-acting injectable, is FDA-approved for advanced prostate cancer, showing 97.9% efficacy in testosterone suppression in a phase 3 study. Common side effects include hot flushing and ...

The MarketWatch News Department was not involved in the creation of this content. TAIPEI, Aug. 28, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the U.S.

TAIPEI, Aug. 28, 2025 /PRNewswire/ -- Foresee Pharmaceuticals (6576.TWO), ("Foresee") announced today that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for ...